Related Experiment Video
Updated: Apr 9, 2026
Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
Published on: June 13, 2025
Data Mining as a Powerful Tool for Creating Novel Drugs in Cardiovascular Medicine: The Importance of a
Masafumi Kitakaze1, Masanori Asakura, Atsushi Nakano
1Department of Cardiovascular Medicine and Development, National Cerebral and Cardiovascular Center, 5-7-1, Fujishirodai, Suita, 565-8565, Japan, kitakaze@zf6.so-net.ne.jp.
Insights
Identifying novel cardiovascular disease drugs is challenging due to complex causes. Data-mining methods analyze clinical data to find potential candidates, requiring a loop between basic research and clinical trials for validation.
Area of Science:
- Cardiovascular Medicine
- Computational Biology
- Drug Discovery
Background:
- Cardiovascular diseases (CVDs) have complex, multifactorial causes, hindering simple cause-and-effect treatment strategies.
- Traditional drug discovery methods in cardiology often rely on induction due to the intricate nature of CVDs.
Purpose of the Study:
- To explore the application of data-mining methods for identifying novel drug candidates in cardiovascular research.
- To highlight the necessity of a cyclical approach integrating clinical data, basic research, and clinical trials.
Main Methods:
- Utilizing data-mining techniques to analyze extensive clinical data, including medical and genetic records.
- Identifying potential drug candidates by uncovering hidden relationships between various parameters and clinical outcomes in cardiovascular disease.
Main Results:
- Data-mining enables the discovery of potential therapeutic targets from complex datasets.
- The identified candidates require validation through basic research and subsequent clinical trials.
Conclusions:
- A 'back-and-forth loop' between clinical observation and basic research is crucial for validating data-mining findings.
- This integrated approach can yield novel cardiovascular drugs, advance basic science understanding, and improve patient outcomes.
Abstract:
Cardiovascular diseases, which lead to cardiovascular events including death, progress with many deleterious pathophysiological sequels. If a cause-and-effect relationship follows a one-to-one relation, we can focus on a cause to treat an effect, but such a relation cannot be applied in cardiovascular diseases. To identify novel drugs in the cardiovascular field, we generally adopt two different strategies: induction and deduction. In the cardiovascular field, it is difficult to use deduction because cardiovascular diseases are caused by many factors, leading us to use induction. In this method, we consider all clinical data, such as medical records or genetic data, and identify a few candidates. Recent computational and mathematical advances enable us to use data-mining methods to uncover hidden relationships between many parameters and clinical outcomes. However, because these candidates are not identified as promoting or inhibiting factors, or as causal or consequent factors of cardiovascular diseases, we need to test them in basic research, and bring them back to the clinical field to test their efficacy in clinical trials. With such a "back-and-forth loop" between clinical observation and basic research, data-mining methods may provide novel strategies leading to new tools for clinicians, basic findings for researchers, and better outcomes for patients.
More Related Videos
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:26Drug Discovery: Overview
01:29Pharmacogenomics: Identification of New Drug Targets
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:16Therapeutic Drug Monitoring: Overview and Classification